Given that oncogenic KRAS is known to induce NRF2 [31] and FSP1 was very recently shown to be a direct transcriptional target of NRF2 [32] in NSCLC mutated in the NRF2 inhibitor kelch-like ECH-associated protein 1 (KEAP1), we next tested whether activating endogenous NRF2 would be sufficient in our cells to induce FSP1. This evidence concerns the gene AIFM2 and non-small cell lung carcinoma.